Study: For complex cases of NMOSD, Ultomiris found safe, effective
Ultomiris safely and effectively reduces relapse risk in complex NMOSD cases and may be safe in combination with rituximab for short periods.| Neuromyelitis News
Ultomiris safely and effectively reduces relapse risk in complex NMOSD cases and may be safe in combination with rituximab for short periods.| Neuromyelitis News
The gut hormone GLP-1 may drive brain inflammation in NMOSD patients, leading to nausea, vomiting, or hiccups, called area postrema syndrome.| Neuromyelitis News
Enspryng was safe and effective for nearly 9 years in people with NMOSD who have antibodies against AQP4, according to data from two trials.| Neuromyelitis News
NMOSD patients who are positive for the anti-AQP4 antibodies were more likely to have other autoimmune diseases, a study in Argentina shows.| Neuromyelitis News
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes inflammation of the optic nerve and the spinal cord.| Neuromyelitis News
Nearly all clinicians (88%) in a U.S. survey have prescribed approved NMOSD treatments for their patients with anti-AQP4 antibodies.| Neuromyelitis News
A discussion with fellow neuromyelitis optica patients prompts columnist Jennifer van Amerom to address her mental health symptoms.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
In patients treated with Enspryng, researchers found the proportions of B-cells was unchanged, suggesting it altered their characteristics.| Neuromyelitis News
